Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions



This article is corrected by:

  1. Errata: Errata Volume 157, Issue 3, 634, Article first published online: 10 August 2007

  • Conflict of interest
    C. Ulrich has acted as a lecturer for Shire Pharmaceuticals and E. Stockfleth has acted as a lecturer/consultant for Shire Pharmaceuticals. All remaining authors declare no conflict of interest.

M. Trakatelli.
E-mail: mtrakatelli@hotmail.com


Summary Nonmelanoma skin cancer (NMSC) is the most common malignancy occurring in white populations. It is currently becoming an important challenge in terms of public health management as the increasing incidence rates will probably have a tremendous impact on healthcare costs. Possible factors driving this rise in NMSC numbers are increases in both acute and prolonged UV exposure together with increasing numbers of older people in the population. A better understanding of NMSC epidemiology in Europe is essential if an evidence-based European-wide public health policy is to be developed. It is obvious this can only be achieved by recording and analysing comparative epidemiological data. Finally, by improving the skin examination training for physicians, developing guidelines and exchanging best practices, a high level of healthcare could be provided for NMSC.